Merck KGaA stock falls on weak Q3, soft outlook
Investing.com -- Shares of Merck KGaA (ETR: MRCG) fell over 4% on Thursday following a mixed reception to its third-quarter ...
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...
Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Morningstar13h
Merck KGaA Expects Sales at Lower End of Outlook Range After Third-Quarter Miss
Merck made an after-tax profit of 812 million euros compared ... We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.